Iovance Biotherapeutics Statistics

Share Statistics

Iovance Biotherapeutics has 333.93M shares outstanding. The number of shares has increased by 17.17% in one year.

Shares Outstanding Shares Outstanding n/a Close	333.93M
Shares Change (YoY) Shares Change (YoY) n/a Close	17.17%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	7.58%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	79.64%
Shares Floating Shares Floating n/a Close	271.49M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	101,116
FTD / Avg. Volume FTD / Avg. Volume n/a Close	0.77%

Short Selling Information

The latest short interest is 86.36M, so 25.86% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	86.36M
Short % of Shares Out Short % of Shares Out n/a Close	25.86%
Short % of Float Short % of Float n/a Close	28.32%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	7.1

Valuation Ratios

The PE ratio is -5.76 and the forward PE ratio is -2.92. Iovance Biotherapeutics's PEG ratio is 0.18.

PE Ratio PE Ratio n/a Close	-5.76
Forward PE Forward PE n/a Close	-2.92
PS Ratio PS Ratio n/a Close	13.07
Forward PS Forward PS n/a Close	0.6
PB Ratio PB Ratio n/a Close	3.02
P/FCF Ratio P/FCF Ratio n/a Close	-5.89
PEG Ratio PEG Ratio n/a Close	0.18

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Iovance Biotherapeutics.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 3.74, with a Debt / Equity ratio of 0.08.

Current Ratio Current Ratio n/a Close	3.74
Quick Ratio Quick Ratio n/a Close	3.31
Debt / Equity Debt / Equity n/a Close	0.08
Debt / EBITDA Debt / EBITDA n/a Close	-0.17
Debt / FCF Debt / FCF n/a Close	-0.16
Interest Coverage Interest Coverage n/a Close	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$195,787.59
Profits Per Employee Profits Per Employee n/a Close	$-444,125.3
Employee Count Employee Count n/a Close	838
Asset Turnover Asset Turnover n/a Close	0.18
Inventory Turnover Inventory Turnover n/a Close	2.41

Taxes

Income Tax Income Tax n/a Close	-2.83M
Effective Tax Rate Effective Tax Rate n/a Close	0.75%

Stock Price Statistics

The stock price has increased by -74.01% in the last 52 weeks. The beta is 0.86, so Iovance Biotherapeutics's price volatility has been higher than the market average.

Beta Beta n/a Close	0.86
52-Week Price Change 52-Week Price Change n/a Close	-74.01%
50-Day Moving Average 50-Day Moving Average n/a Close	2.55
200-Day Moving Average 200-Day Moving Average n/a Close	6.36
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	46.29
Average Volume (20 Days) Average Volume (20 Days) n/a Close	13,161,060

Income Statement

In the last 12 months, Iovance Biotherapeutics had revenue of 164.07M and earned -372.18M in profits. Earnings per share was -1.28.

Revenue Revenue n/a Close	164.07M
Gross Profit Gross Profit n/a Close	40.08M
Operating Income Operating Income n/a Close	-395.28M
Net Income Net Income n/a Close	-372.18M
EBITDA EBITDA n/a Close	-351.67M
EBIT EBIT n/a Close	-395.28M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-1.28

Full Income Statement

Balance Sheet

The company has 115.69M in cash and 58.26M in debt, giving a net cash position of 57.43M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	115.69M
Total Debt Total Debt n/a Close	58.26M
Net Cash Net Cash n/a Close	57.43M
Retained Earnings Retained Earnings n/a Close	-2.38B
Total Assets Total Assets n/a Close	966.74M
Working Capital Working Capital n/a Close	389.96M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -352.98M and capital expenditures -11.07M, giving a free cash flow of -364.05M.

Operating Cash Flow Operating Cash Flow n/a Close	-352.98M
Capital Expenditures Capital Expenditures n/a Close	-11.07M
Free Cash Flow Free Cash Flow n/a Close	-364.05M
FCF Per Share FCF Per Share n/a Close	-1.26

Full Cash Flow Statement

Margins

Gross margin is 24.43%, with operating and profit margins of -240.92% and -226.84%.

Gross Margin Gross Margin n/a Close	24.43%
Operating Margin Operating Margin n/a Close	-240.92%
Pretax Margin Pretax Margin n/a Close	-228.56%
Profit Margin Profit Margin n/a Close	-226.84%
EBITDA Margin EBITDA Margin n/a Close	-214.34%
EBIT Margin EBIT Margin n/a Close	-240.92%
FCF Margin FCF Margin n/a Close	-221.88%

Dividends & Yields

IOVA does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for IOVA is $10, which is 376.2% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$10
Price Target Difference Price Target Difference n/a Close	376.2%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	10

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Sep 26, 2013. It was a backward split with a ratio of 1:100.

Last Split Date Last Split Date n/a Close	Sep 26, 2013
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:100

Scores

Altman Z-Score Altman Z-Score n/a Close	-2.45
Piotroski F-Score Piotroski F-Score n/a Close	4

Iovance Biotherapeutics I... (IOVA)